Global Overactive Bladder Treatment Market - Segmented by Therapy, Disease, and Geography - Growth, Trends, and Forecast (2018 - 2023)

SKU ID : INH- 12347863

Publishing Date : 22-May-2018

No. of pages : 107

PRICE
4250
8750


  • The global overactive bladder treatment market is expected to register a CAGR of about 2.9% over the forecast period, 2018-2023. The overactive bladder treatments includes various therapies like, anticholinergics, mirabegron, etc., that are used to treat the sudden, involuntary contraction of the muscle in the urinary bladder wall leading to urinary urgency, frequency, nocturia, and urge-incontinence.

    Aging Population and Rising Incidence of Diseases Characterized By OAB

    In 2017, there were approximately 950 million people who were 60 years old or above, comprising 13% of the global population, and is growing by about 3% every year. Incontinence generally increases with aging. As per a global population-based survey, the estimated prevalence of overactive bladder (OAB) in Europe and Canada was found to be 12.8% in women and 10.8% in men. OAB has a major negative impact on quality of life and health of the aged population. With the increasing burden of OAB, along with other urinary diseases, the growth of the overactive bladder treatment market is likely to be high. Other factors, such as the development of innovative intravesical therapies and aggressive marketing by pharmaceuticals companies, are also expected to expand the market.

    Undesired Systemic Effects of the Current OAB Treatments

    Anticholinergic have been linked to the burden to dementia or Alzheimer’s disease in a few recent studies. In a recent publication by SL Gray, 3434 participants were studied and a 10-year cumulative dose response relationship was found to exist between the usage of anticholinergic drugs and the risk of developing dementia. Anticholinergic has also been linked with increased mortality and cardiovascular diseases. These factors may deter healthcare providers from using these treatment options. Also the increasing awareness about these side effects among users will lead to the slowdown of the growth of this market.

    North America to Dominate the Market

    North America has dominated the overactive bladder treatment market, which can be primarily attributed to its well-established healthcare industry which has favorable reimbursement of overactive bladder treatment, growing prevalence of the disease with rising age, and the presence of major players. Asia-Pacific region is expected to witness the highest CAGR during the forecast period, due to rising prevalence of bladder overactivity, increasing geriatric population, rising healthcare expenditure, and growing awareness of overactive bladder.

    Major Players: ALLERGAN PLC., ASTELLAS PHARMA INC., COGENTIX MEDICAL INC., ENDO INTERNATIONAL PLC, HISAMITSU PHARMACEUTICAL CO. INC., JOHNSON & JOHNSON, MEDTRONIC PLC, PFIZER INC., SANOFI, AND TEVA PHARMACEUTICAL INDUSTRIES LIMITED, amongst others.

    Reasons to Purchase the Report

    • Current and future overactive bladder treatment market outlook in the developed and emerging markets
    • Analysis of various perspectives of the market with the help of Porter’s five forces analysis
    • The segment that is expected to dominate the market
    • Regions that are expected to witness the fastest growth during the forecast period
    • Identify the latest developments, market shares, and strategies employed by the major market players
    • 3 months analyst support, along with the Market Estimate sheet (in Excel)

    Customization of the Report

    This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.